Clinical trial · Observational
Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients
Human Glioblastoma Multiforme (GBM) Circulating Tumor Cells (CTCs) as Early, Less Invasive Markers of Progression and Response
NCT01135875CI-TRIAL-00012413completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine if tumor cells can be detected in the blood of patients diagnosed with a brain tumor.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma Multiforme | Glioblastoma | CURATED_BROADER | 0.80 |
| Healthy Volunteers | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GBM Patients | Other | — | UNRESOLVED |
| Normal Controls | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- GBM Patients
- description
- GBM Patients with a histologically confirmed or suspected diagnosis of glioblastoma multiforme.
- interventionNames
- Other: GBM Patients
- label
- Normal Controls
- description
- Normal Controls will be adult volunteers who identify themselves as not having been diagnosed with a glioblastoma multiforme.
- interventionNames
- Other: Normal Controls
Primary outcomes (1)
- measure
- Identification of Human GBM CD Antigen Signature.
- timeFrame
- 3 Years
- description
- Already established and stored GBM cell lines will be screened for CD antigens to confirm that a selective cell surface antigen can be identified.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * 18 to 89 years of age * Weight of at least 110 pounds * Able to provide informed consent for self Exclusion Criteria: * Patients with active malignant tumors other than GBM
References
Publications (0)
Data not yet available
No reference posted for this study.